Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2− ABC Patients: A Systematic Review and Meta-Analysis

Abstract

Objective: To evaluate the efficacy and safety of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy (ET) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER-2−) advanced breast cancer (ABC) patients. Methods: We searched clinical trials of CDK4/6 inhibitors combined with ET and calculated the clinical outcomes. Results: HR+/HER-2− ABC patients treated with CDK4/6 inhibitors combined with ET had significantly prolonged progression-free survival (PFS) and improved objective response rate (ORR) and clinical benefit rate (CBR). Conclusions: CDK4/6 inhibitors combined with ET can bring more clinical benefits to ABC patients, and the safety profile is acceptable.